|
Post by peppy on Sept 20, 2016 11:46:30 GMT -5
Afrezza users should plan and execute a march down Wall Street; Wall Street is a 0.7-mile-long street running eight blocks, roughly northwest to southeast, from Broadway to South Street on the East River in the Financial District of Lower Manhattan, New York City, ... Downtown Los Angeles, Honolulu, HI., and any other major city that has a high rate of Type 1 and 2 Diabetics. Read more: mnkd.proboards.com/thread/6268/diabetics-on-afrezza-plan-march?page=2#ixzz4KoakJ2mx I think the idea is ridiculous. I'll stop now. I do know people travel Hawaii guy.
|
|
|
Post by kball on Sept 20, 2016 12:34:26 GMT -5
For all the people poo pooing script counts, can you tell me what the average TRx numbers are for a new novel drug launch in their first 24 months? Has anyone heard of Trokendi XR®? I haven't (it's for epilepsy) but it took ~21 months to reach a total of 20,000 prescriptions. The drug costs ~$600 for a 30 day Rx. Oh and notice the other drugs it competes with that haven't even hit 8,000 total Rxs in the first 21 months. How long did it take Afrezza to reach a total of 20,000 Rxs? ~13 months and that was under Sanofi, who we know didn't do very much to support the drug. docs.google.com/spreadsheets/d/1v9hIa0Eq-SvU57jID3BUdLuVHFxudUnaP_TEyyhdGU8/pubchart?oid=139405975&format=interactiveBut the pool of sufferers of epilepsy pales in comparison to diabetes. Not sure this is a good comparison. Maybe comparing it to about the 8th statin to hit the market or something makes more sense? Either way, not much to get excited about yet.
|
|
|
Post by peppy on Sept 20, 2016 12:48:54 GMT -5
I should just not look. I will disturb the thread. Trokendi XR Topiramate treatment has produced hyperammonemia (in some instances dose-related) in clinical investigational programs in very young pediatric patients (1 month to 24 months) who were treated with adjunctive topiramate for partial onset epilepsy (8% for placebo, 10% for 5 mg/kg/day, 0% for 15 mg/kg/day, 9% for 25 mg/kg/day). TROKENDI XR® is not approved as adjunctive treatment of partial onset seizures in pediatric patients less than 6 years old. In some patients, ammonia was markedly increased (greater than or equal to 50% above upper limit of normal). The hyperammonemia associated with topiramate treatment occurred with and without encephalopathy in placebo-controlled trials, and in an open-label, extension trial of infants with refractory epilepsy. Dose-related hyperammonemia was also observed in the extension trial in pediatric patients up to 2 years old. Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting.
Hyperammonemia with and without encephalopathy has also been observed in postmarketing reports in patients who were taking topiramate without concomitant valproic acid (VPA).
Hyperammonemia (or hyperammonaemia) is a metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to encephalopathy and death. It may be primary or secondary. Ammonia is a substance that contains nitrogen.
.6 Cognitive/Neuropsychiatric Adverse Reactions
Adverse reactions most often associated with the use of topiramate, and therefore expected to be associated with the use of TROKENDI XR® were related to the central nervous system and were observed in the epilepsy population. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties), 2) Psychiatric/behavioral disturbances (e.g.,depression or mood problems), and 3) Somnolence or fatigue. medlibrary.org/lib/rx/meds/trokendi-xr/ -------------------------------------------------------------------------------------------------- So much better than cannabis for seizures disorders. NOT
|
|
|
Post by hawaiiguy42 on Sept 20, 2016 15:11:35 GMT -5
Afrezza users should plan and execute a march down Wall Street; Wall Street is a 0.7-mile-long street running eight blocks, roughly northwest to southeast, from Broadway to South Street on the East River in the Financial District of Lower Manhattan, New York City, ... Downtown Los Angeles, Honolulu, HI., and any other major city that has a high rate of Type 1 and 2 Diabetics. Read more: mnkd.proboards.com/thread/6268/diabetics-on-afrezza-plan-march?page=2#ixzz4KoakJ2mx I think the idea is ridiculous. I'll stop now. I do know people travel Hawaii guy.
Yes, I think you should stop... everyone else gets the idea with the exception of you. You also failed to acknowledge your initial comment which just shows how ridiculous it was!!! Please don't side step the response with... I do know people travel Hawaii guy!!! That is not what you implied so with that being said... yes, you should stop!!!
|
|
|
Post by brotherm1 on Sept 20, 2016 15:28:49 GMT -5
It's amazing how many people here are still so positive. We are in deep poo poo. Scripts should be a little higher at this point. Just read Seeking Alphas new hit piece MannKind: My Public Response To MannKind's Chief Commercial Officer. Even if this guy is half right we are so screwed. The writing is on the wall and there is no time left. Just waiting for the fat lady to sing... Oh and by the way I'm not a basher I have over 14000 shares. God I feel like crying. So if you beleive what this seeking alpha guy says, just follow him and you should make a lot of money? Right?
|
|
|
Post by cjm18 on Sept 20, 2016 15:29:42 GMT -5
For all the people poo pooing script counts, can you tell me what the average TRx numbers are for a new novel drug launch in their first 24 months? Has anyone heard of Trokendi XR®? I haven't (it's for epilepsy) but it took ~21 months to reach a total of 20,000 prescriptions. The drug costs ~$600 for a 30 day Rx. Oh and notice the other drugs it competes with that haven't even hit 8,000 total Rxs in the first 21 months. How long did it take Afrezza to reach a total of 20,000 Rxs? ~13 months and that was under Sanofi, who we know didn't do very much to support the drug. docs.google.com/spreadsheets/d/1v9hIa0Eq-SvU57jID3BUdLuVHFxudUnaP_TEyyhdGU8/pubchart?oid=139405975&format=interactive[ Nice find. Would love to see this for rapid acting analogs like novolog and humalog.
|
|
|
Post by agedhippie on Sept 20, 2016 15:49:04 GMT -5
It's amazing how many people here are still so positive. We are in deep poo poo. Scripts should be a little higher at this point. Just read Seeking Alphas new hit piece MannKind: My Public Response To MannKind's Chief Commercial Officer. Even if this guy is half right we are so screwed. The writing is on the wall and there is no time left. Just waiting for the fat lady to sing... Oh and by the way I'm not a basher I have over 14000 shares. God I feel like crying. So if you beleive what this seeking alpha guy says, just follow him and you should make a lot of money? Right? Easy enough to find out as it's all public record. Look at what else he has posted and his his calls worked out (I haven't looked - I don't care that much).
|
|
|
Post by babaoriley on Sept 20, 2016 16:05:27 GMT -5
We are still blaming Wallstreet and imaginary bad guys? All eyes on script numbers. If they don't start climbing fast it's game over. If scripts do start climbing fast it's game over for short interests and game on for MannKind shareholders. mn, I'm surprised you'd say that. It's been game over for the shorts for years, and it has been anything but. My guess is lots and lots of those Jan 2018 $1 strike call options belong to some shorts who have essentially hedged their bets. They are safe, been saying that for years here - they are far better at playing the market than most longs, who tend to be emotional. Having said that, I hope the shorts do have to rely on their hedges at some point!
|
|
|
Post by oldfishtowner on Sept 20, 2016 17:43:01 GMT -5
For all the people poo pooing script counts, can you tell me what the average TRx numbers are for a new novel drug launch in their first 24 months? Has anyone heard of Trokendi XR®? I haven't (it's for epilepsy) but it took ~21 months to reach a total of 20,000 prescriptions. The drug costs ~$600 for a 30 day Rx. Oh and notice the other drugs it competes with that haven't even hit 8,000 total Rxs in the first 21 months. How long did it take Afrezza to reach a total of 20,000 Rxs? ~13 months and that was under Sanofi, who we know didn't do very much to support the drug. docs.google.com/spreadsheets/d/1v9hIa0Eq-SvU57jID3BUdLuVHFxudUnaP_TEyyhdGU8/pubchart?oid=139405975&format=interactiveI am not sure what you are comparing here but the numbers in the graph are not cumulative scripts. A cumulative number cannot decrease from week to week. month to month or year to year. These graphs are not monotonically increasing, but they should be. But what you are comparing these to is cumulative scripts for Afrezza. I think you are comparing apples and oranges.
|
|
|
Post by harryx1 on Sept 20, 2016 18:09:08 GMT -5
You might be right about the cumulative part. Might not be the greatest comparison with that case but I still don't think that it takes some time to ramp up Rxs numbers.
|
|
|
Post by mnholdem on Sept 20, 2016 20:12:56 GMT -5
If scripts do start climbing fast it's game over for short interests and game on for MannKind shareholders. mn, I'm surprised you'd say that. It's been game over for the shorts for years, and it has been anything but. My guess is lots and lots of those Jan 2018 $1 strike call options belong to some shorts who have essentially hedged their bets. They are safe, been saying that for years here - they are far better at playing the market than most longs, who tend to be emotional. Having said that, I hope the shorts do have to rely on their hedges at some point! An excellent point, baba, which I'm certain liane could have made in less than six words.
|
|
|
Post by sportsrancho on Sept 20, 2016 20:28:55 GMT -5
mn, I'm surprised you'd say that. It's been game over for the shorts for years, and it has been anything but. My guess is lots and lots of those Jan 2018 $1 strike call options belong to some shorts who have essentially hedged their bets. They are safe, been saying that for years here - they are far better at playing the market than most longs, who tend to be emotional. Having said that, I hope the shorts do have to rely on their hedges at some point! An excellent point, baba, which I'm certain liane could have made in less than six words. Really...Laughing out loud.
|
|
|
Post by oldfishtowner on Sept 20, 2016 20:47:51 GMT -5
You might be right about the cumulative part. Might not be the greatest comparison with that case but I still don't think that it takes some time to ramp up Rxs numbers. I'm just guessing here, but if you look at the graphs, it would seem that the first data point is 2 weeks after launch and then data points are at monthly intervals at mid month (straight lines between the data points). So, we are possibly looking at monthly TRx, except for the first data point. If this is correct, then Trokendi XR shows close to 4000 scripts/month at the 1 1/2 month mark. That's roughly 1000 TRx/week. It hits 20,000 cumulative scripts at about 6 months. At 12 months it's over 12,000 scripts/month or roughly 3000/week. If you want to compare, Afrezza's track record isn't even close.
|
|
|
Post by careful2invest on Sept 20, 2016 22:59:26 GMT -5
It's amazing how many people here are still so positive. We are in deep poo poo. Scripts should be a little higher at this point. Just read Seeking Alphas new hit piece MannKind: My Public Response To MannKind's Chief Commercial Officer. Even if this guy is half right we are so screwed. The writing is on the wall and there is no time left. Just waiting for the fat lady to sing... Oh and by the way I'm not a basher I have over 14000 shares. God I feel like crying. "Even if this guy is half right, we are so screwed" Good thing is, he is not right! Mike Castagna's response to a different bashing article recently written by Spencer exposes his deceitful MO. if you have not read it, it is worth checking out. Granted, MNKD is nowhere near where I thought that we would be by now and I invested in this stock over 7 years ago! But I still think that we will get there! Spencer is using every opportunity to kick MNKD and AFREZZA while they are down. No secret there! Spencer is always consistent in creating titles of gloom and doom on every article that he writes about MNKD. (and he has written many) The time alone dedicated to just making charts and graphs is over the top. Yet he claims that he only does it because he likes making charts, predictions and the like! Really?? I don't buy it! That is an excessive amount of time for an individual to dedicate to a supposed worthless, going nowhere little biotech that is trading below .70 cents/ share. Don't you think? It just does not add up! He also screens the responses that are sent to him and does not post responses from readers that call him out on his bogus claims, that would expose him, even when using credible, documented facts and without any rudeness involved. It has happened to me! I no longer engage in dialogue with him. I did write a comment in his latest article that you mentioned letting him know how "great" he is! Ha ha Thats what he wants to hear! GLTA TRUE LONGS!
|
|
|
Post by sophie on Sept 20, 2016 23:23:30 GMT -5
I've never read his column, so this is just conjecture. I try to stay away from the emotional stuff on either side. Based off of what I've read on here about his articles, and others like them on SA, it seems more to me that the reason he keeps picking on Afrezza is because he feels like it was the low hanging fruit that just so happened to have a lot of attraction associated with it.
There is a huge following for Afrezza and it's a pretty polarizing drug. There aren't many interested investors that are middle of the road on it. They're either very long or very short with a few conservatives on either side of the middle. Makes sense for a boom/bust stock. Afrezza might be likened to the Yankees in this regard. Regardless of long/short, people love talking about it. If he's had Afrezza pegged as a failure from the beginning and all he's seen are more signs pointing in that direction, it's not hard to understand why he'd constantly pick on Afrezza. It makes him looks like a genius for calling it right. Added credibility means that more people will respect his opinion (unless he pisses them off, but they still read his work anyway so I doubt he's concerned). It also sounds like it draws a lot of views, even from the very longs on this board that loathe his work. Sounds like he's successfully accomplished his job requirements to me.
|
|